Brief: Pfizer And Innovent Biologics Enter Global Strategic Collaboration To Accelerate Development Of Innovative Oncology Medicines

Innovent Biologics

29/05/2026 24:04

May 28 (Reuters) - PfizerPFE.N:
PFIZER AND INNOVENT BIOLOGICS ENTER GLOBAL STRATEGIC COLLABORATION TO ACCELERATE DEVELOPMENT OF INNOVATIVE ONCOLOGY MEDICINES
PFIZER - AND INNOVENT ENTER GLOBAL LICENSING AND COLLABORATION FOR 12 CANCER MEDICINES
PFIZER - TO RECEIVE EXCLUSIVE GLOBAL LICENSE FOR FOUR PROGRAMS
PFIZER - INNOVENT TO RECEIVE $650 MILLION UPFRONT AND UP TO $9.85 BILLION IN MILESTONES
PFIZER - INNOVENT TO RECEIVE UP TO DOUBLE-DIGIT ROYALTIES ON LICENSED PRODUCT SALES
PFIZER: WILL RECEIVE AN EXCLUSIVE LICENSE OUTSIDE GREATER CHINA FOR FOUR PROGRAMS, AND WILL BE RESPONSIBLE FOR MAJORITY OF DEVELOPMENT COSTS
Source text: ID:nBw4f5pFHa
Further company coverage: 1801.HK

 ((Reuters.Briefs@thomsonreuters.com;))